ClinicalTrials.gg
RecruitingNCT07365072PRIMROSEUpdated Jan 30, 2026

The PRIMROSE Trial

An interventional study of Inspiratory muscle training (POWERBreathe) and Standard Prehab in Cancer, Lung Resection and Inspiratory Muscle Training, sponsored by Swansea Bay University Health Board. Recruiting at 1 site in United Kingdom. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2026-01-30.

Sponsored by Swansea Bay University Health Board · Not applicable, Interventional, and Health services research

How we know

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2025, registered Sep 2025).
  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Smoking is a major cause for developing lung cancer. People diagnosed with lung cancer, may be offered surgery which offers a complete cure. Smoking also damages the lungs and compromises a person's lung function, resulting in shortness of breath. Breathlessness limits the ability to carry out daily physical activities and exercise and makes people vulnerable to developing post procedure complications and even death. Some people with surgically treatable lung cancer have a poor ability to exercise and compromised lung function and are not fit for surgery. They will instead be referred for radiation therapy, chemotherapy or palliative care. Surgery is the preferred treatment option.

The pulmonary rehabilitation program (Prehab) improves fitness levels. In addition, it improves the level of breathlessness, exercise capacity and vulnerability of people with lung cancer, with the aim of making them fit for safe surgery. By adding a breathing training device to the Prehab program, the investigators aim to further improve participants fitness for surgery, lower their risk of developing complications and the time spent in hospital after the procedure. The breathing training device is called an inspiratory muscle training device. The hand-held device helps to train and strengthen the breathing muscles, which are then able to work more effectively. After the procedure, participants may be able to breathe and exercise more easily reducing their risk of developing complications and improving outcomes.

The study will compare two groups of people with lung cancer having surgical removal of part of the lung, at a specialist hospital . One group will receive standard Prehab and inspiratory muscle training with the device prior to the procedure; patients in the second group with receive standard Prehab prior to the procedure. Participants will be followed up for twelve months.

Read the detailed description

To compare inspiratory muscle training (IMT) with standard Prehabilitation (Prehab) to Prehab alone, in people with lung cancer for surgical procedure.

One hundred and thirty-four participants will be recruited for the study (67 for each arm) and with an anticipated attrition rate of 20-25%, one hundred participants will finally be studied.

All adults with lung cancer, aged18 years or over, diagnosed or suspected of non-small cell lung cancer (NSCLC) with surgically resectable disease, who are referred for pre-treatment optimization with Prehab from the lung cancer Multi-Disciplinary Teams (MDTs).

Adults with lung cancer are referred for pre-treatment optimization with Prehab if they meet the following referral criteria: ≥1 Medical Research Council (MRC) dyspnoea score; or ≥1 World Health Organization (WHO) performance status (PS); age ≥ 70 years or frailty index >3; borderline or poor pulmonary function (forced expiratory volume in one second (FEV1) or diffusion capacity for carbon monoxide (DLCO) \<50%); sedentary people despite having adequate FEV1 or DLCO. People will be included in the trial if they are capable of giving consent to participation and aged 18 and over.

Additionally, people who have no contraindications to IMT use.

The aim is to evaluate the impact of thoracic Prehab with IMT compared to standard Prehab in reducing post procedural pulmonary complications following surgical resection in people with lung cancer in a randomised control trial.

Descriptive statistics will be used to summarise participants' characteristics and outcome measures. Statistical analyses will be performed using SPSS statistical software, version 20.0 (IBM Corporation, Armonk, NY, USA). Two-sided significance tests will be used (a\0.05). Data will be presented as mean and standard deviation (SD), or median and interquartile range (IQR) for variables with a skewed distribution. Differences between groups in categorical variables will be tested with Chi square or Fisher's exact test. For continuous data the student's t test or the Mann-Whitney U test will be used. The Wilcoxon signed rank test will be used to compare MIP and QoL at T0 and T1 and T2. Relative risk will be calculated for post procedural pulmonary complications (PPCs) graded 1-V using the Clavien Dindo classification and impact of IMT on the study group compared to the control group. Assuming a 36.7 incidence of PPC after the procedure in the control arm and using a significance level of 0.05 and a power of 80%, 50 participants are required in each arm.

02

Conditions studied

  • Cancer
  • Lung Resection
  • Inspiratory Muscle Training
  • Prehabilitation
  • Respiratory Complications
  • Length of Hospital Stay

Browse trials for

Keywords

  • Inspiratory muscle training
  • Cancer
  • Lung resection
  • Prehabilitation
  • Lung surgery
  • Randomised control trial
  • length of hospital stay
03

In context

Neoplasms

10,838 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.

This study's planned enrollment of 100 is above the median of 60 across 7,716 interventional studies indexed under Neoplasms.

Browse Neoplasms studies →

Lead sponsor

Swansea Bay University Health Board is the lead sponsor of 9 studies on the registry; 5 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: Adults with lung cancer with surgically resectable disease who are referred for pre-treatment optimization with Prehab, from the lung cancer Multi-Disciplinary Teams (MDTs).

The referral criteria for Prehab is below:

  • ≥1 Medical Research Council (MRC) dyspnoea score
  • ≥1 World Health Organization (WHO) performance status (PS)
  • Age ≥ 70 years
  • Frailty index >3
  • Borderline or poor pulmonary function ( (FEV1) \< 50% or diffusion capacity for carbon monoxide (DLCO) \<50%)
  • Sedentary people despite having adequate FEV1 or DLCO
  • People who are eligible for surgical procedures, including endobronchial excision of tumour, or lobectomy, segmental resection, pneumonectomy or wedge resection, either via a minimally invasive approach or a standard thoracotomy approach

Additionally:

  • Participants will be included in the trial if they are capable of providing verbal and written consent for Prehab, and written consent for undergoing a surgical procedure for lung cancer
  • People over 18 years of age
  • All people will be considered regardless of their baseline respiratory muscle strength

Exclusion Criteria: Inclusion criteria not met

  • People diagnosed with other cancers namely, lung cancer, mesothelioma, sarcoma, mediastinal tumours, or benign diseases
  • People who decline Prehab
  • People who do not consent to Prehab, and do not attend Prehab. People who do not consent to surgery
  • People with a high cardiovascular risk for Prehab and awaiting investigations or interventions (including unstable angina and syncope)
  • People with a serious concomitant disorder that would compromise safety during Prehab
  • People with an abdominal hernia or recent abdominal surgery
  • People with a history of spontaneous pneumothorax and/or evidence of large bullae on radiological imaging
  • People with an inability to understand written and/or spoken English (only if carers are able to translate)
  • People with a perforated ear drum
  • People with worsening heart failure signs and symptoms after IMT
  • People with pulmonary hypertension
  • People who have suffered from or likely to suffer from costochondritis
  • If a participant was involved in a similar study, with potential to cause bias or conflict of interest then they will be excluded
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Phase
Not applicable
Primary purpose
Health services research
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Prehab plus device

    Standard Prehab plus inspiratory muscle training device

    Device: Inspiratory muscle training (POWERBreathe) · Other: Standard Prehab

  • Active comparator
    Prehab

    Standard Prehab

    Other: Standard Prehab

Interventions

  • DeviceInspiratory muscle training (POWERBreathe)

    Resistance training for inspiratory muscles prior to procedure.

  • OtherStandard Prehab

    Physical optimisation

06

What researchers measure

Primary outcomes

  1. Post procedure complications

    Post procedure complications following surgical resection in people with lung cancer. This will be graded I-V using the Clavien Dindo Classification. Post procedure complications will be broadly classified as minor (grade 1) and major complications (grade 2-5 where 5 is death). The investigators want to learn from this study, whether an inspiratory muscle trainer helps reduce grade 2 post procedure complications to grade 1 or no complications, and thereby help shorten the length of stay in hospital for people undergoing lung resection surgery. Lower numbers mean a better outcome. Higher numbers mean a worse outcome.

    Time frame: On hospital discharge (assessed up to 2 months)

Secondary outcomes

  1. Measure of Quality of Life

    European Organisation for Research and Treatment of Cancer (EORTC) questionnaire (EOTRC QLQ-30). The scores are transformed into a 0-100 range, where 0 is the lowest possible score and 100 is the highest. A higher score indicates a better outcome for functional and global health scores. However, a higher score on the symptom sales represent a greater burden of symptoms and a worse outcome.

    Time frame: At Prehab initial assessment, periprocedural, at hospital discharge (assessed up to 2 months), 1 month post procedure and 3 months post procedure.

  2. Dyspnoea Score

    Medical research council (MRC) dyspnoea score. This scale is measured from 0 to 4. A higher score means worse outcomes. A lower score means better outcomes.

    Time frame: At Prehab initial assessment, every two weeks whilst undergoing Prehab, periprocedural, at hospital discharge (assessed up to 2 months) and 1 month post procedure.

  3. Performance Status

    World Health Organization (WHO) performance status. This assigns scores from 0 to 5. A higher score indicates worse outcomes and a lower score indicates better outcomes.

    Time frame: At Prehab initial assessment, every two weeks whilst undergoing Prehab, periprocedural, at hospital discharge (assessed up to 2 months), 1 month post procedure.

  4. Thoracoscore

    The Thoracic Surgery Scoring System is used in thoracic procedures to estimate mortality risk. It calculates risk based on the person co-morbidities and procedure. The Thoracoscore ranges from -7.37 to 7.37. A higher score indicates a potential worse outcome/ more risk. A lower score indicates a potential better outcome/ less risk.

    Time frame: At prehab initial assessment and periprocedural.

  5. Frailty Index

    The Clinical Frailty Index is a tool used to assess a persons health status, by measuring the accumulation of health deficits. The scale is 1 to 9. A higher score indicates a greater level frailty and a lower score indicates a lower level of frailty. A higher score is associated with a worse outcome.

    Time frame: At Prehab assessment, every two weeks whilst undergoing Prehab, periprocedural, at hospital discharge (assessed up to 2 months) and 1 month post procedure.

  6. Levels of activity

    Categorised as sedentary, lightly active, moderately active and very active.

    Time frame: On Prehab initial assessment, every two weeks of Prehab, periprocedural, at hospital discharge (assessed up to 2 months) and 1 month post procedure.

  7. Maximum Inspiratory Pressure (MIP)

    Measure of respiratory muscle strength. The higher the number the stronger the respiratory muscles are. For healthy adults, normal ranges are 100 to 120cmH20 for men and 70 to 80 cmH20 in women.

    Time frame: At Prehab initial assessment, periprocedural and at hospital discharge (assessed up to 2 months).

  8. Forced expiratory volume in 1 second (FEV1)

    The amount of air a person can forcefully exhale in the first second after a deep breath. Ranges are categorized by percentage of predicted range. In normal lung function, 80% or higher is expected. In mild airflow obstruction values ranges vary between 50-79% and severe airflow obstruction ranges between 30-49% and very severe impairment below 30%.

    Time frame: At Prehab initial assessment

  9. Transfer factor for carbon monoxide (TLCO)

    Measures the amount of carbon monoxide (CO) transferred per minute from alveolar gas to red blood cells (RBCs). This is considered normal when 76% to 140% of the predicted value is achieved. Mild, moderate and severe ranges are for values below 76%.

    Time frame: At Prehab initial assessment

  10. Mortality

    Death rate

    Time frame: At hospital discharge (assessed up to 2 months), 1 month post procedure , 3 months post procedure and 1 year post procedure

  11. Length of hospital admission

    The numbers of days the participant spent in hospital. A lower number indicates a better outcome. A higher number indicates a worse outcome.

    Time frame: On hospital discharge (assessed up to 2 months).

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Individual participant data will be confidential and study results will be disseminated collectively on completion

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 1,993 non-industry interventional studies with no phase under Neoplasms, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 52. This study's planned 24 months is below that.

Counting every sponsor, half of 2,068 studies reached it within 29 months; a quarter within 13 and three quarters within 52.

Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2025
First posted
Jan 26, 2026
StartActual
May 1, 2025
Primary completionEst.
May 1, 2027
CompletionEst.
May 1, 2027
Last update
Jan 30, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07365072
Lead sponsor
Swansea Bay University Health Board
Responsible party
Sponsor
First posted
Jan 26, 2026
Start date
May 1, 2025
Primary completion
May 1, 2027 (estimated)
Completion
May 1, 2027 (estimated)
Last update
Jan 30, 2026

Study contacts

Ira Goldsmith, Professor
Contact
Ira.Goldsmith@wales.nhs.uk
44 01792 704084
Tracy Jones, Physiotherapy
Contact
tracy.jones6@wales.nhs.uk
44 01792 702222 ext. 23670
Lisa Wakeman
study director · Swansea Bay University Health Board

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion